Dr Sadiq was appointed Senior Lecturer and Honorary Consultant Physician at St George’s in 2003.
He was promoted to Reader in 2011. He graduated in Medicine at Southampton University in 1989, completed his specialist training in Genitourinary Medicine in 2000 and obtained his MD from University College London in 2005 where he investigated the impact of bacterial sexually transmitted infections on antiretroviral susceptible and resistant HIV in the genital tract of individuals receiving antiretroviral therapy.
Dr Sadiq has extensive clinical and academic experience in sexual health and HIV medicine. His current research interests include STI pathogenesis as well as host and microbial personalised medicine technologies ranging from pharmocogenetics to rapid antimicrobial resistance testing and e-health care. He is principal investigator and director of eSTI2 (electronic self-testing instruments for sexually transmitted infections), a multi-institutional microbiological, clinical, engineering and industrial consortium which translates emerging molecular and e-health technologies into deliverable modern microbiological diagnostics.
Dr Sadiq currently leads the St George’s Public Health England Translational and Diagnostic evaluation network across England and Wales. This network links multiple genito-urinary medicine clinics across England and Wales into a diagnostic trials infrastructure with overarching ethical approval to conduct multi-centre studies and evaluations.
Dr Sadiq's work includes investigating personalized medicine technologies for both sexual transmitted infections (STI) and HIV using both microbial and host genomic and biomarker discovery methodologies as well as conducting on-going research into pathogenic causes of genital tract disease. He has developed polymicrobial STI diagnostics in collaboration with industry, including large and small and medium sized enterprises.
Dr Sadiq has led research on the diversity of Cytochrome P450 genetic polymorphisms among black African populations. His work implicated novel haplotype combination of the cyp2B6 isoforms in delaying clearance of the non-nucleoside reverse transcriptase inhibitor, efavirenz. He has discovered novel stop codons associated with loss of cyp2B6 function and demonstrated the vastly differences in prevalence of key pharmacogenetic markers of drug metabolism between important African cohorts living with HIV in the UK.
Dr Sadiq lectures Biomedical Science students on sexually transmitted infections.
Dr Sadiq supervises PhD students.